Flourimetric study on antidiabetic combined drugs; empagliflozin and linagliptin in their pharmaceutical formulation and human plasma
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Flourimetric study on antidiabetic combined drugs; empagliflozin and linagliptin in their pharmaceutical formulation and human plasma
Authors
Keywords
Linagliptin, Empagliflozin, NBD-Cl, Spectroflourimetry
Journal
SPECTROCHIMICA ACTA PART A-MOLECULAR AND BIOMOLECULAR SPECTROSCOPY
Volume 248, Issue -, Pages 119258
Publisher
Elsevier BV
Online
2020-12-01
DOI
10.1016/j.saa.2020.119258
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Validated Voltammetric Method for the Simultaneous Determination of Anti‐diabetic Drugs, Linagliptin and Empagliflozin in Bulk, Pharmaceutical Dosage Forms andBiological Fluids
- (2020) Mohamed Rizk et al. ELECTROANALYSIS
- A highly sensitive and selective spectrofluorimetric method for the determination of manganese at nanotrace levels in some real, environmental, biological, soil, food and pharmaceutical samples using 2-(α-pyridyl)-thioquinaldinamide
- (2018) M. Jamaluddin Ahmed et al. RSC Advances
- Comparative Study Between Multivariate and Univariate Analysis of Two Antidiabetic Combinations
- (2017) Maha F. Abdel-Ghany et al. JOURNAL OF AOAC INTERNATIONAL
- Empagliflozin/Linagliptin: Combination therapy in patients with type 2 diabetes
- (2016) Xueying Tan et al. ANNALES D ENDOCRINOLOGIE
- Initial Combination of Empagliflozin and Linagliptin in Subjects With Type 2 Diabetes
- (2015) Andrew Lewin et al. DIABETES CARE
- Spectrofluorimetric determination of gemifloxacin mesylate and linezolid in pharmaceutical formulations: Application of quinone-based fluorophores and enhanced native fluorescence
- (2014) Bahia Abbas Moussa et al. ACTA PHARMACEUTICA
- The SGLT2 Inhibitor Empagliflozin for the Treatment of Type 2 Diabetes Mellitus: a Bench to Bedside Review
- (2014) Janet B. McGill Diabetes Therapy
- Validity of Meta-analysis in Diabetes: We Need to Be Aware of Its Limitations
- (2013) P. D. Home DIABETES CARE
- Safety, tolerability, pharmacokinetics and pharmacodynamics following 4 weeks' treatment with empagliflozin once daily in patients with type 2 diabetes
- (2013) T. Heise et al. DIABETES OBESITY & METABOLISM
- Linagliptin: farmacology, efficacy and safety in type 2 diabetes treatment
- (2013) Erika Paniago Guedes et al. Diabetology & Metabolic Syndrome
- Linagliptin: A Novel Methylxanthin Based Approved Dipeptidyl Peptidase-4 Inhibitor
- (2012) Ritesh Agrawal et al. CURRENT DRUG TARGETS
- Linagliptin: a novel dipeptidyl peptidase 4 inhibitor with a unique place in therapy
- (2011) Anthony H. Barnett ADVANCES IN THERAPY
- Spectrofluorimetric Determination of Famotidine in Pharmaceutical Preparations and Biological Fluids. Application to Stability Studies
- (2008) M. I. Walash et al. JOURNAL OF FLUORESCENCE
- Spectrofluorometric determination of nicardipine, nifedipine and isradipine in pharmaceutical preparations and biological fluids
- (2008) Sheikha Al-Ghannam et al. Open Chemistry
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now